In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...
Read MoreIn a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...
Read More
In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...
Read More
In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...
Read More
In a nutshell The authors aimed to determine whether palbociclib (Ibrance) could help treat women hormone-receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic (cancer has spread) breast cancer. The addition of palbociclib showed consistent success against breast cancer that had become resistant...
Read More
